Hormone exposure and venous thromboembolism in commercially insured women aged 50 to 64 years.

ABSTRACT:

Background

Menopausal hormone therapy (MHT) can elevate venous thromboembolism (VTE) risk, but less is known about formulations and routes of exposures.

Objective

To estimate hormone-associated VTE risk by route and formulation in exposed and unexposed women aged 50 to 64 years in the US.

Methods

In a nested case-control study of US commercially insured women aged 50 to 64 years (2007-2019), cases were defined as incident VTE diagnoses and matched to 10 controls by date of VTE and age, excluding prior VTE, inferior vena cava filter placement, or anticoagulants. Filled prescriptions in the prior year defined hormone exposures. International Classification of Diseases and Current Procedural Terminology codes identified risk factors and comorbidities

SUBMITTER: Weller SC 

PROVIDER: S-EPMC10182313 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature